This episode contains part 2 of our conversation with Michael Macklin, MD, PharmD, Assistant Professor of Medicine at the University of Chicago, about the Cytokine Crushers region of RheumMadness 2025.In this episode, we focus specifically on the TYK2 in SLE and Oral Anti-IL23 teams. Links to the Cytokine Crushers Scouting Reports:Oral anti-IL23, by collaborating Chicago area rheumatology fellowship programs (Loyola, Northwestern, and the University of Chicago)Long-term outcomes of anifrolumab in SLE, by the Medical University of South Carolina (MUSC) Adult Rheumatology FellowshipTYK2 inhibitor in SLE, by the University of North Carolina (UNC) Adult Rheumatology FellowshipLinks to theMednet.org Q&As about this region:What circumstances would drive you to consider using an oral IL-23 inhibitor over parenteral options for management of psoriasis/PsA?How will you utilize newly FDA approved anifrolumab for SLE in your practice?What is your experience with using oral deucravicitinib for conditions such as recalcitrant facial discoid lupus or recalcitrant lichen planus?To learn more about RheumMadness:https://sites.duke.edu/rheummadness/Subscribe to our newsletter:https://lists.duke.edu/sympa/subscribe/rheummadnessFind us on social media:Bluesky: @rheummadness.bsky.socialInstagram: https://www.instagram.com/rheummadness/X: Follow #RheumMadnessIntro/outro music: Cheery Monday by Kevin MacLeodLink: https://incompetech.filmmusic.io/song/3495-cheery-mondayLicense: http://creativecommons.org/licenses/by/4.0/

Ver todos los episodios